10-KPeriod: FY2021

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2021

Filed February 25, 2022For Securities:MRK

Summary

Merck & Co., Inc. (MRK) reported strong financial performance for the fiscal year ended December 31, 2021, with total sales reaching $48.7 billion, a 17% increase year-over-year, driven primarily by growth in its oncology franchise, particularly Keytruda, and its vaccines business. The company also saw significant contributions from its Animal Health segment and the newly authorized COVID-19 antiviral treatment, molnupiravir. Merck successfully completed strategic acquisitions, including Acceleron Pharma and Pandion Therapeutics, to bolster its pipeline and expand its therapeutic reach in areas like pulmonary diseases and autoimmune disorders. Furthermore, Merck continued to advance its broad pipeline, achieving notable regulatory milestones and receiving over 30 approvals across key markets. The company also completed the spin-off of its Organon business, streamlining its portfolio and allowing for a more focused approach on its core growth drivers. Despite some headwinds from COVID-19 related disruptions, which impacted physician-administered products, Merck demonstrated resilience and a robust commercial execution, positioning itself for continued growth in the pharmaceutical and animal health sectors.

Financial Highlights

57 data points
Beta

Revenue

$48.70B

72.0% Gross Margin

Net Income

$12.35B

25.3% Net Margin

EPS (Diluted)

$5.14

Total Assets

$105.69B

Cash & Equivalents

$8.17B

Free Cash Flow

$8.67B

Financial Statements
Beta
Revenue$48.70B
Cost of Revenue$13.63B
Gross Profit$35.08B
R&D Expenses$12.24B
SG&A Expenses$9.63B
Operating Income$12.35B
Interest Expense$806.00M
Net Income$12.35B
EPS (Basic)$5.16
EPS (Diluted)$5.14
Shares Outstanding (Basic)2.53B
Shares Outstanding (Diluted)2.54B

Key Highlights

  • 1Total sales of $48.7 billion, a 17% increase year-over-year, driven by strong performance in oncology (Keytruda), vaccines (Gardasil/Gardasil 9), and Animal Health.
  • 2Keytruda sales grew 20% to $17.2 billion, underscoring its position as a leading oncology therapy with numerous new indications approved globally.
  • 3Molnupiravir, an oral antiviral for COVID-19, generated $952 million in sales in its first year of authorization.
  • 4Completed strategic acquisitions of Acceleron Pharma ($11.5 billion) and Pandion Therapeutics ($1.9 billion) to enhance its pipeline in oncology, rare diseases, and autoimmune disorders.
  • 5Successfully spun off its Organon business, creating a more focused portfolio and allowing for strategic capital allocation.
  • 6Advanced numerous pipeline candidates, with several in Phase 3 development and under regulatory review, particularly in oncology and infectious diseases.
  • 7Returned $7.5 billion to shareholders in 2021 through dividends and share repurchases, reflecting a commitment to shareholder returns.

Frequently Asked Questions

Merck's financial performance in 2021 was primarily driven by the strong growth of its oncology franchise, led by Keytruda, which saw a 20% increase in sales. The vaccines business, particularly Gardasil/Gardasil 9, also experienced substantial growth. The Animal Health segment continued its upward trajectory, and the launch of molnupiravir contributed significantly to the company's revenue.

Merck's strategic initiatives for future growth include advancing its broad pipeline of investigational medicines and vaccines through rigorous R&D, pursuing strategic business development opportunities such as acquisitions and collaborations to augment its pipeline, and optimizing its operational efficiency. The company is also focused on maximizing the commercial potential of its in-line products and preparing for upcoming launches.

The spin-off of Organon, completed on June 2, 2021, resulted in the historical results of the divested businesses being reflected as discontinued operations in Merck's consolidated financial statements through the date of the spin-off. This move allowed Merck to streamline its portfolio and focus on its core pharmaceutical and animal health businesses.

Merck continues to invest heavily in research and development to support future innovations and long-term growth. R&D expenses in 2021 were $12.2 billion, reflecting higher clinical development spending and increased investment in discovery research and early drug development. The company prioritizes its R&D efforts on candidates that represent breakthrough science and has a robust pipeline with numerous candidates in various stages of development.

Merck faces ongoing pricing pressures globally from managed care organizations and government agencies. The company actively engages in public policy advocacy to demonstrate the value of its medicines and vaccines and works to ensure access and affordability. Strategies include negotiating with payers, implementing value-based pricing approaches where applicable, and demonstrating the clinical benefits of its products.